Matthew A Lunning, DO, MD

Assistant Professor

  • 632 Citations
  • 14 h-Index
If you made any changes in Pure, your changes will be visible here soon.

Fingerprint Fingerprint is based on mining the text of the experts' scientific documents to create an index of weighted terms, which defines the key subjects of each individual researcher.

  • 30 Similar Profiles
Peripheral T-Cell Lymphoma Medicine & Life Sciences
T-Cell Lymphoma Medicine & Life Sciences
Lymphoma, Large B-Cell, Diffuse Medicine & Life Sciences
Lymphoma Medicine & Life Sciences
Follicular Lymphoma Medicine & Life Sciences
Non-Hodgkin's Lymphoma Medicine & Life Sciences
Therapeutics Medicine & Life Sciences
Mantle-Cell Lymphoma Medicine & Life Sciences

Network Recent external collaboration on country level. Dive into details by clicking on the dots.

Research Output 2002 2019

Integrated generation of induced pluripotent stem cells in a low-cost device

Lin, H., Li, Q., Du, Q., Wang, O., Wang, Z., Akert, L., Carlson, M. A., Zhang, C., Subramanian, A., Zhang, C., Lunning, M. A., Li, M. & Lei, Y., Jan 1 2019, In : Biomaterials. 189, p. 23-36 14 p.

Research output: Contribution to journalArticle

Induced Pluripotent Stem Cells
Stem cells
Costs and Cost Analysis
Equipment and Supplies
Eye movements

Integration of supply chain and product design under labor cost uncertainty

Günay, E. E., Lunning, M. A. & Okudan Kremer, G. E., Jan 1 2018, p. 989-994. 6 p.

Research output: Contribution to conferencePaper

Product design
Supply chains
Stochastic programming
1 Citations

Pegaspargase-related high-grade hepatotoxicity in a pediatric-inspired adult acute lymphoblastic leukemia regimen does not predict recurrent hepatotoxicity with subsequent doses

Burke, P. W., Aldoss, I., Lunning, M. A., Devlin, S. M., Tallman, M. S., Pullarkat, V., Mohrbacher, A. M. & Douer, D., Mar 1 2018, In : Leukemia Research. 66, p. 49-56 8 p.

Research output: Contribution to journalArticle

Precursor Cell Lymphoblastic Leukemia-Lymphoma

Phase 1 trial of ibrutinib and carfilzomib combination therapy for relapsed or relapsed and refractory multiple myeloma

Chari, A., Larson, S., Holkova, B., Cornell, R. F., Gasparetto, C., Karanes, C., Matous, J. V., Niesvizky, R., Valent, J., Lunning, M., Usmani, S. Z., Anderson, L. D., Chang, L., Lee, Y., Pak, Y., Salman, Z., Graef, T., Bilotti, E. & Chhabra, S., Apr 5 2018, (Accepted/In press) In : Leukemia and Lymphoma. p. 1-7 7 p.

Research output: Contribution to journalArticle

Multiple Myeloma
Disease-Free Survival